ArticlePloS one2026
Peripheral blood transcriptomes and a single-cell atlas suggest a monocyte-associated immune recovery-failure axis in STEMI.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients with ST-segment elevation myocardial infarction (STEMI) continue to show substantial inflammatory heterogeneity after reperfusion therapy, and recovery trajectories may differ markedly across patients. Compared with traditional diagnostic models, characterizing the dynamic immune trajectory from acute inflammation toward recovery may better identify programs associated with impaired resolution. This study aimed to construct an immune recovery-failure framework that is transferable across cohorts and anchored by single-cell data.
methodsWe integrated six public GEO peripheral-blood bulk transcriptome cohorts and one public single-cell RNA-seq dataset. An acute-to-recovery immune axis was constructed from directionally concordant longitudinal and cross-sectional contrasts, and a recovery-failure phenotype was defined in the discovery longitudinal cohort from paired transcriptomic features. An 18-gene monocyte-associated module was then derived using bulk recovery-failure associations, monocyte specificity, monocyte-state differences, and pseudotime information. External cohorts were used to evaluate temporal transfer and baseline-to-follow-up associations rather than definitive clinical prediction, and the single-cell dataset was used for donor-aware cell-type anchoring and exploratory state-level interpretation.
resultsAmong 81 STEMI patients who met the longitudinal definition criteria, unsupervised stratification classified 35 as recovery-failure patients and 46 as recovery-sufficient patients. We constructed an 18-gene monocyte-associated recovery-failure module. The module distinguished the two transcriptomically defined groups in the discovery cohort and declined from the acute phase toward recovery in external longitudinal cohorts. Baseline module burden was associated with later composition-adjusted inflammatory burden, but this was interpreted as a baseline-to-follow-up association rather than clinical event prediction. At the single-cell level, donor-aggregated lesion-associated shifts were largest in monocytes, and the module decreased along the acute-high-to-recovery-biased monocyte pseudotime direction. In 1,000 matched random monocyte-gene modules, the observed module showed a higher aggregate recovery statistic than nearly all random signatures.
conclusionsWe propose a STEMI immune recovery-failure framework derived from public peripheral-blood transcriptomes, evaluated across independent longitudinal datasets, and linked to monocyte state variation in a public single-cell context. The framework is does not evidence of a causal mechanism or a validated hard-endpoint prediction model; rather, it provides a reproducible transcriptomic description of impaired inflammatory resolution that should be tested prospectively and experimentally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.